![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
ViroLogic and ACLARA Announce Stockholder Approval of Merger Merger Expected to Be Completed By End of Day SOUTH SAN FRANCISCO, Calif. and MOUNTAIN VIEW, Calif., Dec. 10 /PRNewswire-FirstCall/...
Iceland Genomics Corporation and ACLARA Collaborating on Cancer Biomarkers REYKJAVIK, Iceland, Dec. 2 /PRNewswire/ -- Iceland Genomics Corporation (IGC) announced today that they have entered...
ACLARA Announces Third Quarter 2004 Financial Results MOUNTAIN VIEW, Calif. Nov. 9 /PRNewswire-FirstCall/ -- ACLARA BioSciences (NASDAQ:ACLA), today reported financial results for the three and...
ViroLogic and ACLARA to Mail Revised Definitive Proxy for Proposed Merger New Date Set for Stockholder Meetings SOUTH SAN FRANCISCO, Calif. and MOUNTAIN VIEW, Calif., Nov. 8...
Clinical Data Presented at ESMO Shows ETAG(TM) System's Potential in Predicting Response to Cancer Treatment MOUNTAIN VIEW, Calif., Nov. 4 /PRNewswire-FirstCall/ -- ACLARA...
Manuel Hidalgo, M.D., Ph.D., Joins ACLARA BioSciences Scientific Advisory Board Another Distinguished Oncologist Highlights Company's Advancements in Protein-Based Diagnostics MOUNTAIN VIEW...
ViroLogic and ACLARA BioSciences Revise Merger Terms ViroLogic Provides Preliminary Third Quarter Revenue Estimate SOUTH SAN FRANCISCO, Calif. and MOUNTAIN VIEW, Calif., Oct. 19...
ACLARA and GlaxoSmithKline Evaluating eTag(TM) Technology for Patient Selection for Targeted Cancer Therapies MOUNTAIN VIEW, Calif., Oct. 5 /PRNewswire-FirstCall/ -- ACLARA...
ACLARA Data at EORTC-NCI-AACR Symposium Demonstrates ETAG(TM) System Potential in Cancer Drug Development and Treatment Prognosis MOUNTAIN VIEW, Calif. and GENEVA, Sept. 30...
ViroLogic and ACLARA Mail Definitive Proxy for Proposed Merger Date Set for Stockholder Meetings SOUTH SAN FRANCISCO, Calif. and MOUNTAIN VIEW, Calif., Sept. 28 /PRNewswire-FirstCall/...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions